JSB Market Research: Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Toxoplasmosis Therapeutics - Pipeline Assessment and
Market Forecasts to 2019
On 30 th December 2014
Summary
The industry analysis specialist, has released its new report, “Toxoplasmosis Therapeutics -
Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of
information and analysis on the global Toxoplasmosis Therapeutics market. The report
identifies the key trends shaping and driving the global Toxoplasmosis Therapeutics market.
The report also provides insights on the prevalent competitive landscape and the emerging
players expected to significantly alter the market positioning of the current market leaders.
Most importantly, the report provides valuable insights on the pipeline products within the
global Toxoplasmosis Therapeutics sector. This report is built using data and information
sourced from proprietary databases, primary and secondary research and in-house analysis by
GlobalData’s team of industry experts.
You can buy this Report @ http://www.jsbmarketresearch.com/healthcare-medical/rtoxoplasmosis-therapeutics-pipeline-assessment-and-market-forecasts-135206
Scope
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

The report provides information on the key drivers and challenges of the Toxoplasmosis
Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan)
Toxoplasmosis Therapeutics market revenues data from 2006 to 2011, forecast for eight years
to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being
developed and emerging trends by seven key markets. Pipeline candidates fall under major
therapeutic classes.
- Analysis of the current and future competition in the seven key countries Toxoplasmosis
Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is
independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet
needs and the implications for the Toxoplasmosis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Toxoplasmosis Therapeutics
market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline
products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global
Toxoplasmosis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies,
market segments and companies likely to impact the global Toxoplasmosis Therapeutics market
in future.
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

- Formulate effective sales and marketing strategies by understanding the competitive
landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments and strategic
partnerships.
- What’s the next big thing in the global Toxoplasmosis Therapeutics market landscape –
Identify, understand and capitalize.
Other industries we cover:
Advertising and Media
Automotive and Parts
Consumer Goods
Healthcare and Medical
Finance and Banking
Food and Beverages
Travel and Tourism
Textiles and Clothing
SWOT Analysis
Discounts on Market Research Reports till 31st December, 2014
For more inquiries, contact at +91 - 998 729 5242 /
contact@jsbmarketresearch.com
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Table of Content
2 Toxoplasmosis Therapeutics - Introduction
2.1 Disease Overview
2.1.1 Types of Toxoplasma gondii Strain
2.1.2 Life Cycle and Transmission
2.2 Epidemiology
2.2.1 Historic Epidemiology (2006–2011)
2.2.2 Forecast Epidemiology (2011–2019)
2.3 Etiology
2.3.1 Food-borne Transmission
2.3.2 Congenital Transmission
2.3.3 Zoonotic Transmission
2.3.4 Rare Instances of Transmission
2.4 Pathophysiology
2.5 Signs and Symptoms
2.6 Commonly Used Diagnostic Tests
2.6.1 Types of Diagnostic Test
2.7 Treatment and Management Options for Toxoplasmosis
2.7.1 Management of Toxoplasmosis Infection during Gestation
2.7.2 Congenital Toxoplasmosis
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

2.7.3 Ocular Toxoplasmosis
2.7.4 Toxoplasmosis in Immunocompetent Patients
2.8 GlobalData Pipeline Report Guidance
3 Toxoplasmosis Therapeutics - Market Characterization
3.1 Toxoplasmosis Therapeutics Market Size (2006–2011) – Global
3.2 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Global
3.3 Toxoplasmosis Therapeutics Market Size (2006–2011) – The US
3.4 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – The US
3.5 Toxoplasmosis Therapeutics Market Size (2006–2011) – France
3.6 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – France
3.7 Toxoplasmosis Therapeutics Market Size (2006–2011) – Germany
3.8 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Germany
3.9 Toxoplasmosis Therapeutics Market Size (2006–2011) – Italy
3.10 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Italy
3.11 Toxoplasmosis Therapeutics Market Size (2006–2011) – Spain
3.12 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Spain
3.13 Toxoplasmosis Therapeutics Market Size (2006–2011) – The UK
3.14 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – The UK
3.15 Toxoplasmosis Therapeutics Market Size (2006–2011) – Japan
3.16 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Japan
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

3.17 Drivers and Barriers for the Toxoplasmosis Therapeutics Market
3.17.1 Drivers for the Toxoplasmosis Therapeutics Market
3.17.2 Barriers for the Toxoplasmosis Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 Toxoplasmosis Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles of the Marketed Products in the Toxoplasmosis Therapeutics Market
4.3.1 Daraprim (pyrimethamine)
4.3.2 Spiramycin
4.3.3 Sulfadiazine
4.3.4 Folinic Acid
4.4 Key Takeaway
5 Toxoplasmosis Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Toxoplasmosis Therapeutics – Phase III Clinical Pipeline
5.3 Key Takeaway
6 Toxoplasmosis Therapeutics - Clinical Trial Mapping
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

6.1 Clinical Trials by Region and Country
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Clinical Trial Mapping by Sponsors
6.5 Prominent Sponsors
6.6 Companies Participating in Toxoplasmosis Therapeutics Clinical Trials
7 Toxoplasmosis Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Toxoplasmosis Therapeutics: Implications for Future Market Competition
8 Toxoplasmosis Therapeutics Market - Licensing and Partnership Deals
9 Toxoplasmosis Therapeutics Market - KOL Insights, 2012
10 Toxoplasmosis Therapeutics - Appendix
10.1 Market Definitions
10.2 Acronyms
10.3 Bibliography
10.4 Research Methodology
10.4.1 Coverage
10.4.2 Secondary Research
10.4.3 Forecasting
10.4.4 Primary Research
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

10.4.5 Expert Panel Validation
10.5 Contact Us
10.6 Disclaimerr
List Of Tables
Table 1: Toxoplasmosis Therapeutics Market, Global, Prevalence, 2006-2011
Table 2: Toxoplasmosis Therapeutics Market, Global, Prevalence, 2011-2019
Table 3: Alternative Antibiotics Used in Ocular Toxoplasmosis
Table 4: Toxoplasmosis Therapeutics Market, Global, Revenue ($m), 2006-2011
Table 5: Toxoplasmosis Therapeutics Market, Global, Forecast ($m), 2011-2019
Table 6: Toxoplasmosis Therapeutics Market, The US, Revenue ($m), 2006-2011
Table 7: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 2011-2019
Table 8: Toxoplasmosis Therapeutics Market, France, Revenue ($m), 2006-2011
Table 9: Toxoplasmosis Therapeutics Market, France, Forecast ($m), 2011-2019
Table 10: Toxoplasmosis Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 11: Toxoplasmosis Therapeutics Market, Germany, Forecast ($m), 2011-2019
Table 12: Toxoplasmosis Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 13: Toxoplasmosis Therapeutics Market, Italy, Forecast ($m), 2011-2019
Table 14: Toxoplasmosis Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 15: Toxoplasmosis Therapeutics Market, Spain, Forecast ($m), 2011-2019
Table 16: Toxoplasmosis Therapeutics Market, The UK, Revenue ($m), 2006-2011
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Table 17: Toxoplasmosis Therapeutics Market, The UK, Forecast ($m), 2011-2019
Table 18: Toxoplasmosis Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 19: Toxoplasmosis Therapeutics Market, Japan, Forecast ($m), 2011-2019
Table 20: Toxoplasmosis Therapeutics-Phase III Pipeline, 2012
Table 21: Toxoplasmosis Therapeutics - Clinical Trials by Country, 2012
Table 22: Toxoplasmosis Therapeutics - Clinical Trials by Phase, 2012
Table 23: Toxoplasmosis Therapeutics - Clinical Trials by Status, 2012
Table 24: Toxoplasmosis Therapeutics - Overall Sponsors, 2012
Table 25: Toxoplasmosis Therapeutics - Prominent Sponsors, 2012
Table 26: Toxoplasmosis Therapeutics - Company Participating in Therapeutics Clinical Trials,
2012
Table 27: Toxoplasmosis-Global, Deals, 2012
Table 28: Toxoplasmosis Therapeutics Market, Global, KOL Insights, 2012
List Of Figures
Figure 1: Diagnosis Algorithm for Congenital Toxoplasmosis
Figure 2: Approaches for the Treatment of Pregnant Women
Figure 3: Toxoplasmosis Therapeutics Market, Global, Revenue ($m), 2006-2011
Figure 4: Toxoplasmosis Therapeutics Market, Global, Forecast ($m), 2011–2019
Figure 5: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 2006–2011
Figure 6: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 2011–2019
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Figure 7: Toxoplasmosis Therapeutics Market, France, Revenue ($m), 2006–2011
Figure 8: Toxoplasmosis Therapeutics Market, France, Forecast ($m), 2011–2019
Figure 9: Toxoplasmosis Therapeutics Market, Germany, Revenue ($m), 2006–2011
Figure 10: Toxoplasmosis Therapeutics Market, Germany, Forecast ($m), 2011–2019
Figure 11: Toxoplasmosis Therapeutics Market, Italy, Revenue ($m), 2006–2011
Figure 12: Toxoplasmosis Therapeutics Market, Italy, Forecast ($m), 2011–2019
Figure 13: Toxoplasmosis Therapeutics Market, Spain, Revenue ($m), 2006–2011
Figure 14: Toxoplasmosis Therapeutics Market, Spain, Forecast ($m), 2011–2019
Figure 15: Toxoplasmosis Therapeutics Market, The UK, Revenue ($m), 2006–2011
Figure 16: Toxoplasmosis Therapeutics Market, The UK, Forecast ($m), 2011–2019
Figure 17: Toxoplasmosis Therapeutics Market, Japan, Revenue ($m), 2006–2011
Figure 18: Toxoplasmosis Therapeutics Market, Japan, Forecast ($m), 2011–2019
Figure 19: Opportunity and Unmet Need in the Toxoplasmosis Therapeutics Market
Figure 20: Toxoplasmosis Therapeutics - Strategic Competitor Assessment, 2012
Figure 21: Toxoplasmosis Therapeutics - Clinical Trials by Country, 2012
Figure 22: Toxoplasmosis Therapeutics – Clinical Trials by Phase, 2012
Figure 23: Toxoplasmosis Therapeutics – Clinical Trials by Status, 2012
Figure 24: Toxoplasmosis Therapeutics – Overall Sponsors, 2012
Figure 25: Toxoplasmosis Therapeutics Market, Drivers and Barriers, 2012
Figure 26: Implications for Future Market Competition in the Toxoplasmosis Therapeutics
Market, 2012
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Figure 27: GlobalData Market Size Estimation
Figure 28: GlobalData Market Forecasting Model
Report Price:
Licence Type
Price
PDF $ 3995
Site Licence $ 7990
Enterprise Wide Licence $ 11985
Related Reports:
Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to
2019
Acute Spinal Cord Injury (ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Amnesia Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market
Forecasts to 2019
Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Waldenstrms Macroglobulinemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to
2019
Retinoblastoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Ankylosing Spondylitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
You can order this report by calling on +91 - 998 7295 242 or mail us
your contact details at contact@jsbmarketresearch.com
About JSB Market Research:-
JSB market research is a leading player in the market of research report distribution. It is onestop-shop
for all information related to market research for any sector of the industry. Along
with providing in-depth analysis though reports, JSB market research also provides regular
updates of the market though newsletters. Our reports are a well-researched work of market
researchers with an extensive knowledge and a good level of market experience.
To know more on Toxoplasmosis Therapeutics - Pipeline Assessment and Market
Forecasts to 2019
http://www.jsbmarketresearch.com/healthcare-medical/r-toxoplasmosistherapeutics-pipeline-assessment-and-market-forecasts-135206
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/